A series of social media posts from U.S. Sen. Bernie Sanders sent shares of Eli Lilly and Co. briefly tumbling to a seven-month low.
Sanders' Twitter account posted a link to a Washington Post article detailing the decades-long price increase of a Lilly insulin called Humalog. The price of Humalog has risen from $21 a vial to more than $250 during the last 20 years, according to the Post.
The tweets went out to Sanders' 2.7 million Twitter followers. They were not signed by Sanders. Sanders' account posted several more messages that were sharply critical of the Indianapolis drugmaker.
Lilly in a statement defended its pricing of Humalog, noting the product's revenue has been lagging.
Sanders also targeted Lilly competitor Novo Nordisk, a Danish drugmaker whose insulin price has risen at a rate similar to Humalog, according to the Post.
What is next then?
No comments:
Post a Comment